Buy
Average AnalystHold
Top AnalystBearish
Stock Target AdvisorBuy
Average UserUSD 1.25
-0.05 (-3.85%)
USD 0.11B
1.34M
USD 6.65(+432.14%)
Based on the Editas Medicine Inc stock forecast from 11 analysts, the average analyst target price for Editas Medicine Inc is USD 6.65 over the next 12 months. Editas Medicine Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Editas Medicine Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Editas Medicine Inc’s stock price was USD 1.25. Editas Medicine Inc’s stock price has changed by -4.58% over the past week, -13.79% over the past month and -82.42% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.